Home

This site is intended for US healthcare professionals only.

Copy Current URL

Secondary AML

Learn about the seriousness of sAML

and its impact on treatment decisions.

Offer your patients a finite treatment duration with VYXEOS.¹

VYXEOS delivers a synergistic combination

of daunorubicin and cytarabine.¹

See VYXEOS clinical data, including study details, 3-year HSCT overall survival, and real-world evidence.